Background: Topoisomerase I and II (topo I and II) are enzymes which alter the topological state of DNA through DNA strand cleavage, strand passage and religation. They participate in most aspects of DNA metabolism and are therefore vital to the cell undergoing division. Only one form of topo I has been identified whereas two isoenzymes of topo II have been described: the a form (170 kDa protein) and P form (180 kDa protein). Both topo II isoenzymes have distinct nuclear localisation, are regulated independently, differ in their responsiveness to inhibitors and are differentially expressed in drug resistant cell lines.
Introduction
Since the discovery in the mid 1980s that several of the most effective anticancer drugs such as doxorubicin (DOX), etoposide (VP-16) and camptothecin (CPT) interrupt the normal catalytic cycle of topoisomerase I (CPT) and H (DOX, VP-16) (topo I and H) [1] [2] [3] , these key enzymes have become important new targets for rational design of new anticancer drugs. What are topoisomerases; why are they important targets in cancer chemotherapy; what kinds of inhibitors are available; why do we need new inhibitors and what types of inhibitors should be designed for future use? These are the main questions which will be discussed in this review.
What are topoisomerases?
Topoisomerases are enzymes that change the topology (or conformation) of a segment of DNA by a complex catalytic cycle which involves DNA strand cleavage, strand passage and religation [4] . These enzymes are essential to the cell because of the nature of the structure of the double helix which, although normally stored highly complexed as chromatin, can impose topological problems (supercoiling) when it is unwound and processed. Topoisomerases alter the linking number of DNA -the number of times one strand of double helix crosses over the other strand -and thereby modify levels of supercoiling [5] . Topo I changes Unking number by a factor of 1 as only one strand of double helix passes through an enzyme produced gap or cleavage site created in the other strand. Topo II changes linking number by a factor of 2 as both strands of one section of double helix pass through a double stranded cleavage site. Since topo II cleaves both strands it can support more complex reactions. It can knot or unknot a length of DNA. If two DNA molecules become intertwined (such as at the end of DNA replication when two identical daughter molecules are synthesized), topo II can separate these by repeated rounds of strand passing activity. Topo II can also decatenate circular DNA molecules which are interlocked (or catenated). A summary of these properties is shown in Table 1 . The molecular biology of topoisomerase I and II
Topoisomerase I
Topo I is a 100 kDa monomeric protein encoded by a single copy gene located on 20ql2-13.2 and requires phosphorylation for full expression of its activity [6] .
The enzyme is heavily concentrated in the nucleolus and is associated with transcriptionally active regions of the genome [7, 8] . It is also found in the nucleoplasm and does not show fluctuations during different phases in the cell cycle [9] . Interest in topo I as a selective target has been revived due to two sets of recent findings. First, that chronic lymphoblastic leukaemia and several types of lymphoma express higher levels of enzyme than normal tissue [10] . Second, that human colon cancer xenografts and primary human colon adenocarcinoma biopsies contain significantly higher levels of enzyme than normal colon, especially the more advanced Dukes Cl-3 grade specimens [11] . As well, human colon cancer xenografts have been shown to be exquisitely sensitive to the topo I inhibitor 20 (RS)-9-amino-camptothecin [11] . Topo I is involved in gene expression (transcription) and DNA replication, where it travels ahead of transcription complexes or replication forks relaxing positive supercoils and allowing the double helix to swivel about itself [12] [13] [14] .
Topoisomerase II
There are now known to be at least two topo II isoenzymes in vertebrates but not in lower eukaryotes: the a form which is a 170 kDa homodimeric protein encoded by a single copy gene located on chromosome 17q21-22, and the newly described (3 form which has a molecular weight of 180 kDa (although frequently degrades to 150 kDa upon isolation) and has been mapped to chromosome 3p24 [15] [16] [17] . Due to the difficulty in isolating the |3 form, most studies performed to date using purified enzymes probably refer either exclusively to the properties of the a form or to a mixture of the a form and partially degraded |3 form [16] . Topo II is an integral part of the nuclear matrix and the mitotic chromosome scaffold localised at the bases of radial loop domains of mitotic chromosomes [18, 19] . Using monoclonal antibodies specific to the a and (3 forms it has recently been reported that the two isoenzymes have a unique pattern of distribution within the nucleus [20] . The 180 kDa protein is found almost exclusively in the nucleolus and belongs to the structural elements of the nucleolar remnant, whereas the 170 kDa protein is localised in the nucleoplasm. Several factors are involved in post-translational regulation of topo II activity, including poly (ADP-ribosylation) which inhibits catalytic activity [21] , and phosphorylation which can enhance catalytic activity [22] . Expression of topo II is highly dependent on the proliferative state of cells and stage in the cell cycle [23] . Topo Ha is non-detectable in G o cells, increases dramatically during S phase, peaks in G 2 -M and then declines. By contrast the P form remains constant throughout the cell cycle and is detectable in G o cells. Log phase cells are more abundant in the 170 kDa protein whereas plateau phase cells are more abundant in the 180 kDa protein. This tight proliferation dependent control is disrupted in certain tumour cell lines [24] . Human tumours have been shown to express higher levels of topo II mRNA than normal tissues [25] , with increased expression of the a form (170 kDa) being associated with the most aggressive and highly proliferative neoplasms [26, 27] .
The main biological functions of topo II are in the segregation of daughter chromosomes, the construction of chromosome structure, DNA replication, gene transcription and DNA recombination [12, [28] [29] [30] [31] . Studies with yeast mutants reveal that the presence of topo II but not topo I is essential for cell viability [32] . Treatments which increase the level of topo II (24 hr pretreatment with the topo I inhibitor CPT-11) augment the activity of topo II inhibitors in human xenografts and this may provide the basis for synergistic combinations of topo I and II inhibitors [33] . However, close attention will have to be paid to drug scheduling since co-administration of topo I and II inhibitors may actually produce antagonism [34, 35] .
No strict consensus sequences have been identified for the binding of topo I and II to DNA, although an intact duplex cleavage substrate [36] , as well as the presence of the passage helix, is essential in the case of topo II [37] . It is more likely that both topo I and II recognise topologjcal features, in particular the crossover points between one double helix and another at a supercoil [38] .
Inhibition of topoisomerase I and II

Cleavable complex formation
Identification of topoisomerases as a critical target in the mechanism of anticancer drug action was achieved in the mid 1980s following on from earlier observations that certain compounds induced unique DNA lesions in cancer cells in vitro [39] . Using the alkaline elution assay these were characterised as protein associated DNA single and double stranded breaks [40] [41] [42] [43] [44] . Subsequently, the protein attached to the break sites on the nucleic acid was shown to be a topoisomerase [3, 45] . Drugs were demonstrated to be participating in the DNA damage by interfering with the breakage-reunion reaction in the enzymes' catalytic cycle, trapping the protein in a putative reaction intermediate which is termed the cleavable complex (cc) [1] . This leaves the topoisomerase molecule covalently bound to DNA, masking the cleavage site. Treatment of cleavable complexes with protein denaturants such as the detergent SDS or strong alkali reveal the protein associated DNA breaks [32] . On the basis that the enzyme itself is responsible for inflicting DNA damage it follows that inhibitors should be more effective against cell lines which express higher levels of protein.
Indeed several studies have shown that this is the case, although this is not always a unanimous observation [46] [47] [48] . Topo II inhibitors stabilize a covalent bond between a tyrosine residue on the protein and the 5' phosphoryl end of each broken strand of DNA with a 4 base pair stagger between cleavage sites on complementary strands [1, 2] . Topo I inhibitors stabilize a covalent bond between a tyrosine residue on the protein and the 3' phosphoryl end of the single strand it breaks [49] . Formation of cleavable complexes is due to inhibition of the religation phase of the breakage-reunion reaction rather than by promotion of cleavage [50, 51] . An interesting feature of the cc is its reversibility. This can be achieved once the drug inhibitor has been removed from the medium, after treatment with high salt concentration (0.5 M sodium chloride) or after exposure to elevated temperature (65°C) [52] .
DNA cleavage site analysis
Analysis of cleavage sites induced by different topo inhibitors has revealed that they tend to be unique to a specific class of compound [32] . Identification of these cleavage sites has important ramifications since with many combinations of drugs and cell lines there is no clear relationship between bulk DNA damage and cytotoxicity, raising the possibility that certain cleavages are more critical for tumour cell kill than others [53] . For example the c-myc proto-oncogene is 20-fold more sensitive to m-AMSA induced cleavage than the overall genome [54, 55] . Once these important cleavage sites have been identified they could provide a more selective target for future rational drug design.
Cleavage sites for individual drugs appear with a very high frequency beside the same base. In the case of topo II inhibitors, DOX has a local base sequence preference for A at the 3' terminus of the break (-1); ellipticines have a preference for T at -1; VM-26 a preference for C at -1 and m-AMSA a preference for A at +1 (5' terminus of the break) [56] [57] [58] . In extensive studies with DOX and the SV 40 minichromosome, cleavage sites were located primarily in the nuclear matrix associated regions. DOX stabilized 97 sites which were all unique to the drug and different from the 90 sites produced by the enzyme alone [56] . CPT, the topo I inhibitor, has a local base sequence requirement for G at +1 or T at -1 [59, 60] . It predominately increases the intensity of the majority of background cleavages produced by the enzyme alone. A small fraction of sites are diminished, some are unchanged and some are unique to the drug. In an analysis of over 100 topo I sites it was observed that cleavages occurred at sequences sharing local twist angle variations [61] .
To explain the local base sequence selectivity of topo poisons the following model has been proposed [56] . Initially a tyrosine residue on the protein intercalates DNA at a potential cleavage site. Then the drug inhibitor binds to DNA at the same site and as a consequence shifts the tyrosine moiety towards the phosphate backbone to produce a covalent bond and the cleavable complex. With DOX the presence of A at -1 would facilitate the formation of a covalent bond whereas C, G and T would not. The same explanation would apply for the base preferences of other topo poisons.
Mechanism of cell kill
It remains unclear exactly how a reversible DNA lesion such as the topo cc results in cell kill. CPT is 1000-fold more effective against cells in S-phase compared to cells in other phases of the cell cycle [62] . Despite this, CPT produces a similar level of DNA damage to S-phase cells in relation to G, phase cells [63] . Moreover, Chinese hamster ovary DC3F cells and L1210 cells can actually be protected completely from CPT cytotoxicity by the DNA polymerase inhibitor aphidicolin even though there is no reduction in DNA damage, indicating that cc formation can be uncoupled from cell death [64, 65] . Indeed, CPT-induced cell death can be demonstrated to have a requirement for ongoing DNA synthesis [66] . This has led to hypothesis that cytotoxicity is mediated through the collision of replication forks with cleavable complexes, converting a non-cytotoxic reversible DNA lesion (the cc) into a cytotoxic lesion (a single strand DNA break) [67] . CPT has been shown to induce DNA cleavage at replication forks [68] .
Topo II inhibitors do not exhibit the same S-phase specificity as topo I inhibitors [69] and aphidicolin only has a modest effect on the cytotoxicity of m-AMSA and VP-16 [64] . In addition, ongoing RNA transcription appears to be involved in the mechanism of cell kill by topo II inhibitors [67] . Several treatments can reduce the cytotoxicity of topo II inhibitors without affecting the level of drug induced DNA damage indicating the nature of the processes required downstream of cc formation in order for cell death to occur. These factors include: an energy requirement for ATP [70] ; protein synthesis [71] ; RNA transcription [72] and the presence of calcium ions [73] . Although topo II inhibitors acti-vate programmed cell death (apoptosis) [74, 75] , the kinetics of cell death suggest that this is not an early event following cc formation [34] . More specific processes are indicated such as inhibition of p34 cdc2 kinase [76] and illegitimate DNA recombination, which is then followed by G 2 arrest and apoptosis [34, 73] .
Induction of differentiation
Topoisomerases have been proposed to play a role in the early events of the differentiation process. During maturation topo II (a and p") levels can be demonstrated to decrease progressively both in vitro [77] and in vivo [78] . Topo II has been shown to be a target for phosphorylation by protein kinase C (PKC) in phorbol ester induced differentiation in HL 60 cells [79] . A number of topo II inhibitors and CPT have the ability to induce differentiation [80] . This responseis associated with G 2 arrest in U-937 promonodytic leukemia cells treated with m-AMSA and VP-16 [8l] but with increased accumulation of cells in GQ/G, in WEHI-3B D+ monomyelocytic leukemia cells exposed to VM-26 [82] . Despite the use of sub-cytotoxic drug concentrations, DNA damage is apparent [83, 84] . A more complex mechanism of action than simple enzyme inhibition is implicated. In HL-60 cells stimulated to differentiate with phorbol 12-myristate 13-acetate (PMA), VP-16 induced DNA cleavage was reduced 10-fold [85] . Nevertheless, there was no change in the activity of topo II present in 0.35 M NaCl nuclear extracts [85] . An alteration in the structure of cellular chromatin reducing topo II binding affinity to DNA was proposed to explain this result. In the same cell type (the HL-205 variant) the induction of differentiation by novobiocin (a topo II inhibitor) was believed to be mediated indirectly via a protein kinase (probably PKC) acting on topo II rather than by a direct effect of the drug [86] .
Classification of topoisomerase inhibitors
Established topo II active agents fall into the following classes: anthracyclines (lead compound, DOX); anthracenediones (mitoxantrone); anthrapyrazoles (biantrazole); actinomycins (actinomycin D, mixed topo I and II inhibitor); acridines (m-AMSA); ellipticines (9-hydroxy-ellipticine); and epipodophyllotoxins (VP-16 and VM-26). Only one major class specific to topo I has been described: the camptothecins (lead compound CPT). These clinically active drugs are characterised by binding to DNA through intercalation; by acting almost exclusively on topo I or II and by working through the cleavable complex [1] [2] [3] 49] . VP-16 and CPT are not intercalators and are believed to bind to DNA only after it has been cleaved by a topoisomerase [87] . A comprehensive list of new inhibitors which have appeared over the past five years is shown in Table 2 . It is interesting to note that the majority of these do not conform to the pattern described above. There are a number of new compounds which do not bind significantly to DNA but which, nevertheless, stabilize cleavable complexes (genistein, epicatechin, Table 2 [88, 89] ). There are also compounds which stabilize cleavable complexes with both topo I and II (saintopin, AzalQD [90, 91] ). Most intriguing are the inhibitors How these novel compounds act as inhibitors of the catalytic activity of topo I and II without forming the cc is not fully understood. Novobiocin works as a competitive inhibitor of ATP binding to topo II [103] and suramin couples onto topo II through electrostatic interactions [102] . Netropsin binds to the minor groove of DNA with high affinity and appears to inhibit topo II by preventing the enzyme associating with DNA [100] .
The mechanism of cell kill by these novel inhibitors also appears to be quite distinct from that of established compounds [104, 105] . Exposure to ICRF-154 (see Table 2 ) resulted in a progressive accumulation of RPMI 8402 cells with 4N DNA content and abnormal chromosomes [34] . The most sensitive phase of the cell cycle was G 2 -M where cells exhibited multilobed nuclei. This pattern of cell death is consistent with this compound working by inhibiting the strand passing activity of topo II essential for the segregation of daughter chromosomes and for the maintenance of normal chromosomal structure.
Cancer cell drug resistance to topoisomerase inhibitors
It is generally recognised that the major reason for the failure of topo inhibitors to produce long term cures in the clinic is the problem of drug resistance [106] . Since a large number of inhibitors are of natural origin, or related in structure to natural products, the phenomenon of multi-drug resistance (MDR) mediated by expression of the plasma membrane phospho-glycoprotein P-170 is strongly implicated [107] . MDR has been the subject of many recent reviews and will not be discussed here further [108, 109] . Another important consideration dictating chemosensitivity is the proliferation dependent expression of topo n. A tumour containing only a small growth fraction is likely to be less responsive to topo II poisons which act predominately through the a form due to a presumed reduction in protein expression. This assumption was recently shown to hold true for human lymphocytes collected from patients with B cell chronic lymphoblastic leukaemia (CLL) and B or T lymphocytes from normal donors. In vitro exposure to DOX resulted in no detectable DNA cleavage; and when measured these cells were shown to have undetectable levels of topo II [10] .
Cell lines selected for specific resistance to topo inhibitors have proved useful not only in elucidating biochemical mechanisms of drug resistance (atypical multi-drug resistance, altered topo drug resistance, AT) [110] but have provided fundamental insights into these enzymes as a target. Examples of cell lines exhibiting AT mechanisms of resistance to topo I and II poisons are shown in Table 3 . On a cautionary note, it must be stressed that these data refer to in vitro derived resistance in cell lines expressing levels of resistance much higher than are expected to be found clinically [111] .
An examination of the models reported on in Table  3 reveal the basis of a trend during the development of increasing levels of resistance. Lines expressing low levels of resistance (and possibly clinically relevant levels of resistance) actually show no detectable alteration in the expression or functionality of their topoisomerases (HN-1/VP2; A549/CPT [112, 113] , Table 3 ). Intermediate levels of resistance generally result in a quantitative reduction in expression of catalytically normal enzyme (Calcl8/AMSA [114] ). An interesting exception is the KB-VP 2 cell line which although exhibiting a 20-fold reduction in the expression of topo n, has unaltered topo II catalytic activity due to a 14-18 fold increase in protein phosphorylation [115] . High levels of resistance produce genetically stable mutant enzymes with altered catalytic function and greatly reduced ability to stabilize the cc in response to inhibitors (CEM/VM-1-5, CHOCpf [116, 117] ). These geneticchanges, which mostly appear as point mutations in a single allele, may be highly specific for the selecting drug [118] [119] [120] . Also important in determining chemosensitivity to topo II inhibitors is likely to be the ratio of the 170 kDa protein versus the 180 kDa protein [15, 121] . Studies have shown that pl80 is 3-fold less sensitive to VM-26 compared to pl70 [122] and that mitoxantrone resistance may be conferred by loss of the drug sensitive pl80 isoenzyme [123] .
Rational design of new topoisomerase inhibitors
The majority of clinically active topoisomerase poisons were not developed on the basis of rational drug design against a specific cellular target [124] . Most of these drugs do not act exclusively through topoisomerases and therefore cannot be considered 'clean' enzyme inhibitors. DOX has been proposed to have at least three additional mechanisms of action, including the generation of free radicals through quinone reduction, and these clearly contribute to the high degree of host toxicity of this drug, particularly cardiotoxicity [125] [126] [127] [128] . Ellipticines, acridines and the epipodophyllotoxins can generate reactive intermediates and bind to DNA covalently through oxidative metabolism and may also mediate cytotoxicity (and host tissue toxicity) through these processes [129] [130] [131] . Actinomycin D need not necessarily work through topoisomerase inhibition based on studies with yeast mutants [132] . Newer agents are being produced either through random screening programmes [97] or from analogue development, based on arbitrary chemical modifications around a proven structure [133, 134] . Recently, an attempt has been made to prospectively design new compounds using molecular modelling and a common topo II pharmacophore identified from existing inhibitors [135] . The resultant compound, azatoxin, was an analogue hybrid between the VP-16 aglycone and ellipticine. Azatoxin did not bind to DNA but was both an inhibitor of catalytic activity and induced an extensive and individual profile of DNA cleavage [135] . Ultimate drug design would involve solving the crystalline structure of a topo/drug/nucleic acid ternary complex, then synthesizing the optimal molecule to occupy the drug binding site on the protein [136] . This approach is now being applied to the rational design of thymidylate synthetase inhibitors [137] . Unfortunately, with the topoisomerases this information is not available and would be difficult to interpret if it was, since there is probably more than one binding site on topo II, and several crystal structures would have to be solved [138] . Equally important to protein binding is the nature of the interaction of the drug with sequence elements on DNA [139] . Consequently, the choice of oligonucleotide used in x-ray crystallography studies would be critical.
Classic structure-activity studies with congeneric series of compounds have provided clues to the relative importance of the above interactions. Firstly, whilst the majority of topo poisons bind to DNA by intercalation not all intercalators stabilize the cc, as examplified by ethidium bromide [32] . Indeed, suppression of cleavage is seen when compounds in a series exhibit a very high DNA binding affinity constant, whereas cleavage stabilization can be completely lost when binding affinity drops below a certain level [3, 140] . High affinity DNA binders can also exhibit host toxicity due to non-selective inhibition of other DNA dependent enzyme activities [141] . Structural studies with intercalators reveal that most of these drugs contain a side chain which projects from one of the grooves of DNA allowing for a direct contact with the topoisomerase protein [124] . Removal of the 9-hydroxy external group from ellipticines alters this interaction and produces inactive analogues [140] . Within a series of amsacrines the substituent at the 1' position on the 9-anilino group has been shown to be critical for stabilization of the cc [142, 143] . The presence of a further substituent on the 9-anilino ring system can have profound effects on biologic activity. When placed in the ortho position (2', OCH 3 , o-AMSA) inactive derivatives result but when placed in the meta position (m-AMSA) active derivatives result. Similarly, the 9-hydroxy position on the anthracycline ring system is important for a hydrogen bonding interaction with topo II and for stabilization of the cc [144] . Together, these data suggest a highly specific protein binding mechanism which is sensitive to slight changes in the structure of the drug molecule. Furthermore, it is increasingly likely that this interac-tion occurs at different points on the topoisomerase protein for different classes of inhibitors. Two independent human myeloid leukaemia cell lines selected for high levels of resistance to m-AMSA, but which were only nominally cross-resistant to other topo II inhibitors such as VP-16 and DOX, both had a point mutation in TOP 2 gene encoding for the 170 kDa form resulting in arginine 486 being converted to lysine. It was concluded that this domain of the protein must be involved in trapping the m-AMSA cleavable complex but that other domains were involved with other inhibitors [120] . This point mutation is identical to the nal 31 mutation in the E. coli gyrase B gene which confers resistance to cleavable complex formation by nalidixic acid [145] . Sequence comparison between human and yeast topo II indicates that Tyr804 is the active site tyrosine that becomes covalently bound to DNA during strand cleavage [146] . Rational design of new amsacrine molecules around the proposed protein binding site (1' position on the 9-anilino) has been disappointingly unsuccessful in overcoming a similar resistance mechanism in the HL 60/AMSA cell line which also has a mutant topo II enzyme [147] . Mutations in the TOP 1 gene encoding for topo I lead to CPT resistance [148] . Thus, compounds which work through the cc may be susceptible to mutant enzymes and this may prove to be an intractable problem since the fundamental nature of the protein binding site(s) will have changed. Perhaps a more real problem for topo inhibitors which work through the cc is the recent suggestion that they are responsible for therapy-related acute myeloid leukemia characterised by highly specific chromosomal abnormalities such as a 9; 11 translocation [149] . This has been attributed to the DNA cleavage properties of the topo inhibitors which produce chromosomal aberrations such as sister chromatid exchanges [150] .
Structure-activity studies with a series of quinolones have shown that stabilization of the cc and inhibition of catalytic activity can be uncoupled [151] . The majority of the newly described compounds highlighted in Table  2 fall into the category of selective inhibitors of catalytic activity. Considering the potential problems of cc formation, this may be a sensible approach to follow, and indeed compounds within this class have a) been shown to be non-cross resistant in MDR and AT-MDR cell lines (fostriecin and anthracenyl-peptides; 98,152) and b) exhibit in vivo activity against xenografts (anthracenyl-peptides, unpublished observation). However, an increase in the level of expression of the topoisomerase being targeted could theoretically result in drug resistance to a catalytic inhibitor, analogous to methotrexate resistance. Frequently, alterations in the regulation of one topoisomerase is compensated by alterations in the expression of the opposite number topoisomerase (i.e., a 3-fold decrease in topo II in Calc 18/AMSA is compensated for by a 3-fold increase in topo I). Thus, combined inhibitors of the catalytic activity of topo I and n may have a natural advantage in circumventing these potential drug resistance mechanisms. Alternatively, synergistic treatment combinations of a catalytic inhibitor followed by a DNA cleavage inducer may be a possibility.
Therefore, perhaps the ideal topoisomerase active drug of the future will be quite a different prospect from existing compounds. They may act as clean inhibitors of the catalytic activity of both topo I and II without forming the cc or by inducing minimal, sequence selective DNA damage. They may only have a limited affinity for binding to DNA and will not operate through secondary mechanisms such as free radical formation and covalent binding to DNA. Probably, most important of all, these new compounds will be non cross-resistant in MDR and AT-MDR cell lines. Since these compounds will be selective inhibitors, a more limited spectrum of clinical activity is to be expected. Greater importance will have to be placed on clinical determinations to identify optimal patient subpopulations and disease types which express high levels of topoisomerases [153] . Finally, treatments with the eventual aim of altering the expression of topo I and II selectively in tumours cells should be increasingly investigated [154] [155] [156] .
